|Articles|May 28, 2009
Novartis buys Ebewe injectables unit
28 May 2009
Advertisement
Novartis AG has agreed to buy Ebewe Pharma's injectables unit for $1.2 billion in an all-cash transaction.
The deal excludes Ebewe's neurological products business but will enable Novartis to add generic cancer drugs to its offerings.
Ebewe, based in Austria, generated EUR 188 million in sales last year and EUR 53 million in operating profit.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
2
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
3
FDA Approves Expanded Indication of Jaypirca for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
4
Patients Avoid Care as Healthcare Costs Rise: Report
5
